LipExoGen
Showing Products 1-30 of 51 Result
AL-0001-10ML
HSPC/Chol/DSPE-mPEG2000/MPL (56.2/38.5/4.3/1, mol/mol) Liposomes
Immunogenic PEGylated liposomes containing 1 mol% of the Toll-like receptor 4 (TLR4) agonist monophosphoryl lipid A (MPL), which is effective as an immune-stimulating adjuvant. This product is particularly useful in preclinical applications including vaccination, immunotherapy, or other areas of immunology research, especially in situations where a immunologically-active agent is meant to be administered for the purpose of stimulating an immune response. The liposome vehicle is very similar to that of the well-characterized Doxil® formulation in terms of lipid composition, which is desirable for translational purposes.
2373.50 €
AL-0001-2ML
HSPC/Chol/DSPE-mPEG2000/MPL (56.2/38.5/4.3/1, mol/mol) Liposomes
Immunogenic PEGylated liposomes containing 1 mol% of the Toll-like receptor 4 (TLR4) agonist monophosphoryl lipid A (MPL), which is effective as an immune-stimulating adjuvant. This product is particularly useful in preclinical applications including vaccination, immunotherapy, or other areas of immunology research, especially in situations where a immunologically-active agent is meant to be administered for the purpose of stimulating an immune response. The liposome vehicle is very similar to that of the well-characterized Doxil® formulation in terms of lipid composition, which is desirable for translational purposes.
757.50 €
CAL-0001-2ML
DOTAP/DOPE (50/50, mol/mol) Liposomes
DOTAP/DOPE (50/50, mol/mol) liposomes, 5 mM, hydrated in distilled water and extruded to 70-12- nm.We synthesize custom liposomes like this. To see a full list of our formulation capabilities, click here.Or, contact us today to request a custom formulation.
600.95 €
DLL-0005-A1-10ML
Adavosertib Liposomes, Formulation WD4
PEGylated liposomes containing Wee-1 kinase inhibitor adavosertib (MK1775; AZD1775), remote loaded by an ammonium sulfate gradient. The lipid composition of the liposomes is the same as Doxil. Sterile filtered and supplied ready for use in preclinical studies in rodents or in vitro. Adavosertib is a potent, ATP-competitive Wee-1 kinase inhibitor, which hinders the G2 DNA damage response checkpoint and is reported to enhance cytotoxic effects of several compounds including 5-FU and NSC 613327. For preclinical research use only.
5044.95 €
DLL-0005-A1-2ML
Adavosertib Liposomes, Formulation WD4
PEGylated liposomes containing Wee-1 kinase inhibitor adavosertib (MK1775; AZD1775), remote loaded by an ammonium sulfate gradient. The lipid composition of the liposomes is the same as Doxil. Sterile filtered and supplied ready for use in preclinical studies in rodents or in vitro. Adavosertib is a potent, ATP-competitive Wee-1 kinase inhibitor, which hinders the G2 DNA damage response checkpoint and is reported to enhance cytotoxic effects of several compounds including 5-FU and NSC 613327. For preclinical research use only.
1004.95 €
DLL-0008-1A-100MG
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
3024.95 €
DLL-0008-1A-10MG
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
600.95 €
DLL-0008-1A-25MG
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
1004.95 €
DLL-0008-1B-100MG
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
3226.95 €
DLL-0008-1B-10MG
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
802.95 €
DLL-0008-1B-25MG
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
1206.95 €
DLL-0008-1C-100MG
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
3226.95 €
DLL-0008-1C-10MG
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
802.95 €
DLL-0008-1C-25MG
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
1206.95 €
DLL-0008-1D-100MG
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
3226.95 €
DLL-0008-1D-10MG
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
802.95 €
DLL-0008-1D-25MG
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
1206.95 €
DLL-0008-1E-10MG
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
802.95 €
DLL-0008-1E-25MG
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
1206.95 €
DLL-0008-1E-50MG
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
3226.95 €
DLL-0010-10ML
DT-061 (SMAP) Liposomes, Formulation TT-40
PEGylated liposomes containing PP2A activator DT-061 (SMAP). DT-061 is an activator of protein phosphatase 2A (PP2A). PP2A regulates many cellular signaling pathways including MAPK/ERK, Wnt/β-catenin, Akt/mTOR, GSK3β, p53/apoptosis, cell cycle, and others. This product can be used in vitro or in vivo for studying the effects of PP2A activation and could be applied to preclinical therapy of KRAS-mutant and MYC-driven tumors. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
3024.95 €
DLL-0010-2ML
DT-061 (SMAP) Liposomes, Formulation TT-40
PEGylated liposomes containing PP2A activator DT-061 (SMAP). DT-061 is an activator of protein phosphatase 2A (PP2A). PP2A regulates many cellular signaling pathways including MAPK/ERK, Wnt/β-catenin, Akt/mTOR, GSK3β, p53/apoptosis, cell cycle, and others. This product can be used in vitro or in vivo for studying the effects of PP2A activation and could be applied to preclinical therapy of KRAS-mutant and MYC-driven tumors. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
1004.95 €
DLL-0011-10ML
Tanespimycin (17-AAG) Liposomes, Formulation XT28.1
PEGylated liposomes containing Hsp90 inhibitor Tanespimycin (17-AAG). Tanespimycin exhibits 100-fold higher binding affinity to HSP90 derived from tumor cells vs normal cells, and induces apoptosis, necrosis, autophagy, and mitophagy. Tanespimycin is insoluble in aqueous media. This product is a pre-formulated liposomal version of Tanespimycin which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
3024.95 €
DLL-0011-2ML
Tanespimycin (17-AAG) Liposomes, Formulation XT28.1
PEGylated liposomes containing Hsp90 inhibitor Tanespimycin (17-AAG). Tanespimycin exhibits 100-fold higher binding affinity to HSP90 derived from tumor cells vs normal cells, and induces apoptosis, necrosis, autophagy, and mitophagy. Tanespimycin is insoluble in aqueous media. This product is a pre-formulated liposomal version of Tanespimycin which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
1004.95 €
DLL-0012-1A-1MG
Nexturastat A Liposomes
PEGylated liposomes containing Nexturastat A. Nexturastat A is a potent and selective HDAC6 inhibitor (IC50: 5 nM), with >190-fold selectivity over other HDACs. This product is a pre-formulated liposomal version of Nexturastat A which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
600.95 €
DLL-0012-1A-5MG
Nexturastat A Liposomes
PEGylated liposomes containing Nexturastat A. Nexturastat A is a potent and selective HDAC6 inhibitor (IC50: 5 nM), with >190-fold selectivity over other HDACs. This product is a pre-formulated liposomal version of Nexturastat A which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
1004.95 €
DLL-0012-1B-1MG
Nexturastat A Liposomes
PEGylated liposomes containing Nexturastat A. Nexturastat A is a potent and selective HDAC6 inhibitor (IC50: 5 nM), with >190-fold selectivity over other HDACs. This product is a pre-formulated liposomal version of Nexturastat A which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
802.95 €
DLL-0012-1B-5MG
Nexturastat A Liposomes
PEGylated liposomes containing Nexturastat A. Nexturastat A is a potent and selective HDAC6 inhibitor (IC50: 5 nM), with >190-fold selectivity over other HDACs. This product is a pre-formulated liposomal version of Nexturastat A which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
1206.95 €
DLL-0012-1C-1MG
Nexturastat A Liposomes
PEGylated liposomes containing Nexturastat A. Nexturastat A is a potent and selective HDAC6 inhibitor (IC50: 5 nM), with >190-fold selectivity over other HDACs. This product is a pre-formulated liposomal version of Nexturastat A which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
802.95 €
DLL-0012-1C-5MG
Nexturastat A Liposomes
PEGylated liposomes containing Nexturastat A. Nexturastat A is a potent and selective HDAC6 inhibitor (IC50: 5 nM), with >190-fold selectivity over other HDACs. This product is a pre-formulated liposomal version of Nexturastat A which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.